Baseline menopausal hormone therapy history and subsequent recorded urticaria among UK Biobank women: a population-based prospective cohort study
This prospective cohort study of over 266,000 UK Biobank women found that a history of menopausal hormone therapy is associated with a modestly increased risk of subsequent recorded urticaria, though the small absolute risk difference and potential for residual confounding limit immediate clinical implications and causal conclusions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For many women, the transition into menopause brings a shift in how the body feels and functions, often leading to the consideration of hormone therapy to ease symptoms like hot flashes. This treatment, known as menopausal hormone therapy, involves taking medications to replace the estrogen and progesterone that the body stops making naturally. While these medications are widely used, the long-term effects on the immune system and skin health remain a subject of ongoing inquiry. One specific area of interest is urticaria, a condition commonly known as hives, which causes itchy, raised welts on the skin. Although hives can be triggered by many things, from food allergies to stress, scientists have long wondered if the hormonal changes associated with menopause and its treatments might play a role in their development. Understanding this connection is important because women make up a large portion of those who suffer from chronic skin conditions, and clarifying whether a common medication influences this risk could help doctors and patients make more informed choices.
To investigate this question, researchers turned to a massive, long-term health database known as the UK Biobank, which tracks the lives and health records of hundreds of thousands of people across the United Kingdom. They focused their attention on over 266,000 women who had provided detailed information about their medical history before the study began. The researchers specifically looked at whether these women had ever used menopausal hormone therapy and then followed their health records for more than a decade to see who developed a medical diagnosis of hives. The study was designed to be very careful, ensuring that they only counted women who had not already been diagnosed with hives before the study started, and they tracked the first time a diagnosis appeared in hospital or doctor records. By comparing the women who had used hormone therapy with those who had never used it, the team could see if there was a difference in how often hives appeared in the two groups.
The results showed a small but noticeable difference between the two groups. Among the women who had a history of using hormone therapy, the rate of new hives diagnoses was slightly higher than among those who had never used the treatment. Specifically, for every 1,000 years of observation, about 0.76 women with a history of hormone therapy developed hives, compared to about 0.65 women without that history. When the researchers adjusted for other factors that could influence the results, such as age, body weight, smoking habits, and other medical conditions, the link remained. The data suggested that women with a history of hormone therapy had about a 16 percent higher rate of being diagnosed with hives later in life compared to those who never took the medication. This finding held true even when the researchers looked at different subgroups, such as women who were past menopause, or when they checked if the results changed if they waited a couple of years after the baseline to start counting.
However, the researchers were very clear that this finding does not prove that hormone therapy causes hives. The study was observational, meaning it watched what happened naturally without assigning treatments, so other hidden factors could still be at play. For instance, women who choose to take hormone therapy might differ in other ways from those who do not, perhaps having different health habits or accessing medical care more frequently, which could lead to more diagnoses being recorded. The researchers also noted that the actual increase in risk was quite small in absolute terms. While the percentage increase was statistically significant, the real-world difference meant that for a large group of women, only a very small number of extra cases of hives were observed. Furthermore, the study could not distinguish between different types of hives, such as short-term allergic reactions versus long-term chronic conditions, because the medical records used did not contain that level of detail.
The study also looked at other skin and hair conditions to see if the pattern was specific to hives. They examined a condition called alopecia areata, which causes patchy hair loss, and found no clear link to hormone therapy, suggesting that the association with hives was not just a general effect on all skin or hair issues. Despite the careful statistical methods used to balance the groups and account for known differences, the authors emphasized that the possibility of unmeasured factors influencing the results remains. They concluded that while there is a measurable association between a history of menopausal hormone therapy and a slightly higher rate of recorded hives, the evidence is not strong enough to say the treatment causes the condition or to change current medical advice. The findings serve as a prompt for further research rather than a final answer, highlighting the need for future studies that can track medication use more closely over time and confirm whether a direct biological link exists.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.